Perrigo Company plc faces operational risks and high leverage while maintaining its 22-year dividend growth record. See why ...
Dutch Bros shows strong revenue and same-store sales growth, fast store expansion to 2029, and 33% upside potential. Click ...
If you’re a Class 8 truck maker or dealer, a carrier, or a spot market freight hauler, industry conditions are improving, ...
Alithya delivers $130.9 M in new Bookings(1) and maintains a strong cash position as the company pursues its shift toward higher‑value, complex ...
Getty Realty Corp. (NYSE:GTY) Q4 2025 Earnings Call Transcript February 12, 2026 Operator: Good morning, and welcome to the Getty Realty Corp. fourth quarter 2025 earnings call. This call is being ...
RotoBaller on MSN
Dynasty Fantasy Football Outlooks: 2nd Year Player Rankings (2026)
What better way to prepare for the future than by learning from our past? Let's take a look at how the 2025 rookie class stacks up as they enter year two. But first, for a deeper dive into dynasty ...
Balancing these concerns, there was divergence between Shell and BP as they announced full-year 2025 financial results. Shell, for many years the more successful operator, increased its Q4 dividend by ...
NWM Plc's Common Equity Tier 1 (CET1) ratio was 18.4% at 31 December 2025, compared with 18.2% at 31 December 2024. The increase in the year was largely driven by higher CET1 capital, partially offset ...
Magna delivered solid fourth-quarter results, reflecting disciplined execution, and improved operating performance. Year-over-year comparison (fourth quarter of 2025 versus fourth quarter of 2024): ...
NWM Plc's Common Equity Tier 1 (CET1) ratio was 18.4% at 31 December 2025, compared with 18.2% at 31 December 2024. The increase in the year was largely driven by higher CET1 capital, partially offset ...
Cooper-Standard Holdings Inc. (NYSE: CPS) today reported results for the fourth quarter and full year 2025. Fourth ...
(PRESS RELEASE) BASEL, 13-Feb-2026 — / EuropaWire / — Novartis has announced final Phase III results from the ALIGN study evaluating Vanrafia (atrasentan) in adults with IgA nephropathy (IgAN), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results